Trials / Completed
CompletedNCT00904449
Open Label Assessment of Long-Term Safety and Utility
An Open-Label Assessment of the Long-Term Safety and Utility of Numorphan® for the Relief of Moderate to Severe Pain in Patients With Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to monitor the long-term analgesic effectiveness, safety, and utility of oxymorphone ER for the relief of moderate to severe pain due to cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxymorphone ER | 10mg, 20mg, and 40mg PO |
Timeline
- Start date
- 2001-04-01
- Primary completion
- 2002-12-01
- Completion
- 2002-12-01
- First posted
- 2009-05-19
- Last updated
- 2010-02-10
Source: ClinicalTrials.gov record NCT00904449. Inclusion in this directory is not an endorsement.